Summary Points – Why Melphalan is no longer standard of initial care in elderly patients
{"Image DocumentName": "Summary Points \u2013 Why Melphalan is no longer standard of initial care in elderly patients", "Image ImageDescription": "Novel agents are equivalent if not superior to MP+novel agent. MP+ results in greater short term toxicity. As survival is extended in myeloma, using melphalan upfront is not desirable due to marrow toxicity. Melphalan can lead to increased second primary malignancies.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}